Pharmacotherapeutic management of pediatric gliomas: Current and upcoming strategies

Pediatric Drugs

Volumn 15, Issue 1, 2013, Pages 29-42

  Hummel, Trent R ^a   Chow, Lionel M ^a   Fouladi, Maryam ^a   Franz, David ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CILENGITIDE; CISPLATIN; CIXUTUMUMAB; CRENOLANIB; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETOPOSIDE; GEFITINIB; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; IRINOTECAN; LENALIDOMIDE; LOMUSTINE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MK 0752; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PREDNISONE; PROCARBAZINE; RAPAMYCIN; TEMOZOLOMIDE; TEMSIROLIMUS; TROFOSFAMIDE; UNINDEXED DRUG; VINCRISTINE; VORINOSTAT;

ADJUVANT THERAPY; BRAIN TUMOR; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER REGISTRY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHILD CARE; CHILDHOOD CANCER; GLIOBLASTOMA; GLIOMA; HEALTH CARE QUALITY; MAINTENANCE CHEMOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; STANDARD; SURVIVAL RATE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; GLIOMA; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL;

EID: 84873349485     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.1007/s40272-012-0002-4     Document Type: Review

References (171)

1. Altekruse SF, Kosary CL, Krapcho M, et al. editors. SEER cancer statistics review, 1975-2007, National Cancer Institute. Bethesda (MD) (based on November 2009 SEER data submission, posted to the SEER web site, 2010). http://seer.cancer.gov/csr/1975-2007/. Accessed 8 Nov 2012.
2. Central Brain Tumor Registry of the United States (CBTRUS). CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004-2007. February 2011: Hinsdale (IL). http://www.CBTRUS.org. Accessed 8 Nov 2012.
3. Louis DN, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97-109.
4. Bondy ML, et al. Brain tumor epidemiology: consensus from the brain tumor epidemiology consortium. Cancer. 2008;113(7 suppl):1953-68.
5. Neglia JP, et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst. 2006;98(21):1528-37.
6. Salvati M, et al. Radio-induced gliomas: 20-year experience and critical review of the pathology. J Neurooncol. 2008;89(2):169-77.
7. Varley JM. Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat. 2003;21(3):313-20.
8. Leonard JR, et al. The role of surgical biopsy in the diagnosis of glioma in individuals with neurofibromatosis-1. Neurology. 2006;67(8):1509-12.
9. Guillamo JS, et al. Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients. Brain. 2003;126(Pt 1):152-60.
10. Melean G, et al. Genetic insights into familial tumors of the nervous system. Am J Med Genet C Semin Med Genet. 2004;129C(1):74-84.
11. Aydin D, et al. Mobile phone use and brain tumors in children and adolescents: a multicenter case-control study. J Natl Cancer Inst. 2011;103(16):1264-76.
12. Wolff JE, et al. Preradiation chemotherapy for pediatric patients with high-grade glioma. Cancer. 2002;94(1):264-71.
13. Finlay JL, et al. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group. J Clin Oncol. 1995;13(1):112-23.
14. Kramm CM, et al. Improved survival after gross total resection of malignant gliomas in pediatric patients from the HIT-GBM studies. Anticancer Res. 2006;26(5B):3773-9.
15. Sposto R, et al. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group. J Neurooncol. 1989;7(2):165-77.
16. Finlay JL, Zacharoulis S. The treatment of high grade gliomas and diffuse intrinsic pontine tumors of childhood and adolescence: a historical-and futuristic-perspective. J Neurooncol. 2005;75(3):253-66.
17. Fouladi M, et al. Outcome of children with centrally reviewed low-grade gliomas treated with chemotherapy with or without radiotherapy on children's cancer group high-grade glioma study CCG-945. Cancer. 2003;98(6):1243-52.
18. Wisoff JH, et al. Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the children's cancer group trial no. CCG-945. J Neurosurg. 1998;89(1):52-9.
19. MacDonald TJ, et al. Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma: final analysis of children's cancer group study 9933. Cancer. 2005;104(12):2862-71.
20. Wolff JE, et al. Subpopulations of malignant gliomas in pediatric patients: analysis of the HIT-GBM database. J Neurooncol. 2008;87(2):155-64.
21. Wolff JE, et al. Oral trofosfamide and etoposide in pediatric patients with glioblastoma multiforme. Cancer. 2000;89(10):2131-7.
22. Wolff JE, et al. Maintenance treatment with interferon-gamma and low-dose cyclophosphamide for pediatric high-grade glioma. J Neurooncol. 2006;79(3):315-21.
23. Wolff JE, et al. Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma. J Neurooncol. 2008;90(3):309-14.
24. Wolff JE, et al. High dose methotrexate for pediatric high grade glioma: results of the HIT-GBM-D pilot study. J Neurooncol. 2011;102(3):433-42.
25. Friedman HS, et al. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res. 1995;55(13):2853-7.
26. Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-96.
27. Hegi ME, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003.
28. Stupp R, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-66.
29. Cohen KJ, et al. Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol. 2011;13(3):317-23.
30. Broniscer A, et al. Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J Neurooncol. 2006;76(3):313-9.
31. Cohen KJ, et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. Neuro Oncol. 2011;13(4):410-6.
32. Lashford LS, et al. Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol. 2002;20(24):4684-91.
33. Vredenburgh JJ, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25(30):4722-9.
34. Ali SA, et al. Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases. J Neurosurg. 2008;109(2):268-72.
35. Bokstein F, Shpigel S, Blumenthal DT. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer. 2008;112(10):2267-73.
36. Gururangan S, et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a pediatric brain tumor consortium study. J Clin Oncol. 2010;28(18):3069-75.
37. Narayana A, et al. Bevacizumab in recurrent high-grade pediatric gliomas. Neuro Oncol. 2010;12(9):985-90.
38. Ellis LM, Hicklin DJ. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res. 2008;14(20):6371-5.
39. Gorski DH, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999;59(14):3374-8.
40. Lee CG, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 2000;60(19):5565-70.
41. Yuan F, et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA. 1996;93(25):14765-70.
42. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061-8.
43. Parsons DW, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807-12.
44. Gallia GL, et al. PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res. 2006;4(10):709-14.
45. Newcomb EW, et al. Incidence of p14ARF gene deletion in high-grade adult and pediatric astrocytomas. Hum Pathol. 2000;31(1):115-9.
46. Pollack IF, et al. Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort. Cancer Res. 2001;61(20):7404-7.
47. Pollack IF, et al. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort. J Neurosurg. 2006;105(5 Suppl.):418-24.
48. Voldborg BR, et al. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol. 1997;8(12):1197-206.
49. Weiss WA. Genetics of brain tumors. Curr Opin Pediatr. 2000;12(6):543-8.
50. Wong KK, et al. Genome-wide allelic imbalance analysis of pediatric gliomas by single nucleotide polymorphic allele array. Cancer Res. 2006;66(23):11172-8.
51. Liang ML, et al. Tyrosine kinase expression in pediatric high grade astrocytoma. J Neurooncol. 2008;87(3):247-53.
52. Khatua S, et al. Overexpression of the EGFR/FKBP12/HIF-2alpha pathway identified in childhood astrocytomas by angiogenesis gene profiling. Cancer Res. 2003;63(8):1865-70.
53. Geoerger B, et al. Innovative therapies for children with cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro Oncol. 2011;13(1):109-18.
54. Daw NC, et al. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2005;23(25):6172-80.
55. Bode U, Buchen M, Warmuth-Metz M, et al. Final report of a phase II trial of nimotuzumab in the treatment of refractory and relapsed high-grade gliomas in children and adolescents. J Clin Oncol. 2006;24(Suppl. 18):1522.
56. Maher EA, et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev. 2001;15(11):1311-33.
57. Zhu Y, Parada LF. The molecular and genetic basis of neurological tumours. Nat Rev Cancer. 2002;2(8):616-26.
58. Holland EC, et al. Signaling control of mRNA translation in cancer pathogenesis. Oncogene. 2004;23(18):3138-44.
59. Holland EC, et al. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet. 2000;25(1):55-7.
60. Faury D, et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol. 2007;25(10):1196-208.
61. Children's Oncology Group. MK2206 in treating younger patients with recurrent or refractory solid tumors or leukemia [ClinicalTrials.gov identifier NCT01231919]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov. Accessed 8 Nov 2012.
62. Yoshiji H, et al. Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res. 1999;59(17):4413-8.
63. Pediatric Brain Tumor Consortium. Enzastaurin in treating young patients with refractory primary CNS tumors [ClinicalTrials.gov identifier NCT00503724]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov. Accessed 8 Nov 2012.
64. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004;4(5):335-48.
65. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12(1):9-22.
66. Geoerger B, et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res. 2001;61(4):1527-32.
67. Iwamaru A, et al. Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells. Oncogene. 2007;26(13):1840-51.
68. Geoerger B, et al. Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma. Eur J Cancer. 2012;48(2):253-62.
69. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004;4(7):505-18.
70. Naidu KA, et al. Antiproliferative and apoptotic effect of ascorbyl stearate in human glioblastoma multiforme cells: modulation of insulin-like growth factor-I receptor (IGF-IR) expression. J Neurooncol. 2001;54(1):15-22.
71. Liu TJ, et al. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther. 2007;6(4):1357-67.
72. Andrews DW, et al. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol. 2001;19(8):2189-200.
73. Children's Oncology Group. Cixutumumab and temsirolimus in treating young patients with solid tumors that have recurred or not responded to treatment [ClinicalTrials.gov identifier NCT00880282]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov. Accessed 8 Nov 2012.
74. Paugh BS, et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol. 2010;28(18):3061-8.
75. Pollack IF, et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a pediatric brain tumor consortium report. Neuro Oncol. 2007;9(2):145-60.
76. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128(4):683-92.
77. Marks P, et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001;1(3):194-202.
78. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene. 2007;26(9):1351-6.
79. Weidle UH, Grossmann A. Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment. Anticancer Res. 2000;20(3A):1471-85.
80. Xu J, et al. Vorinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures. J Neurooncol. 2011;105(2):241-51.
81. Yin D, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res. 2007;13(3):1045-52.
82. Fouladi M, et al. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol. 2010;28(22):3623-9.
83. Su JM, et al. Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a Children's Oncology Group report. Clin Cancer Res. 2011;17(3):589-97.
84. Children's Oncology Group. Vorinostat and radiation therapy followed by maintenance therapy with vorinostat in treating younger patients with newly diagnosed pontine glioma [ClinicalTrials.gov identifier NCT01189266]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www. clinicaltrials.gov. Accessed 1 Sep 2011.
85. Hummel TR, Wagner LM, Ahern CH, et al. A pediatric phase I trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group Phase I Consortium Study [abstract no. 9579]. J Clin Oncol 2011; 29Suppl.
86. Greider CW. Telomeres do D-loop-T-loop. Cell. 1999;97(4):419-22.
87. de Lange T. How telomeres solve the end-protection problem. Science. 2009;326(5955):948-52.
88. Boldrini L, et al. Telomerase activity and hTERT mRNA expression in glial tumors. Int J Oncol. 2006;28(6):1555-60.
89. Huang F, et al. Correlation of clinical features and telomerase activity in human gliomas. J Neurooncol. 1999;43(2):137-42.
90. Maes L, et al. Relation between telomerase activity, hTERT and telomere length for intracranial tumours. Oncol Rep. 2007;18(6):1571-6.
91. Children's Oncology Group. Imetelstat sodium in treating young patients with refractory or recurrent solid tumors or lymphoma [ClinicalTrials.gov identifier NCT01273090]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov. Accessed 8 Nov 2012.
92. Tabatabai G, et al. Targeting integrins in malignant glioma. Target Oncol. 2010;5(3):175-81.
93. Reardon DA, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs. 2008;17(8):1225-35.
94. MacDonald TJ, et al. Phase I clinical trial of cilengitide in children with refractory brain tumors: pediatric brain tumor consortium study PBTC-012. J Clin Oncol. 2008;26(6):919-24.
95. Lambret CO. Cilengitide in combination with irradiation in children with diffuse intrinsic pontine glioma (CILENT-0902) [ClinicalTrials.gov identifier NCT01165333]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov. Accessed 8 Nov 2012.
96. Martin-Luther-Universität Halle-Wittenberg. Cilengitide and metronomic temozolomide for relapsed or refractory high grade gliomas or diffuse intrinsic pontine gliomas in children and adolescents (HGG-CilMetro) [ClinicalTrials.gov identifier NCT01517776]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov. Accessed 8 Nov 2012.
97. Radtke F, Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer. 2003;3(10):756-67.
98. Iso T, Kedes L, Hamamori Y. HES and HERP families: multiple effectors of the Notch signaling pathway. J Cell Physiol. 2003;194(3):237-55.
99. Purow BW, et al. Expression of notch-1 and its ligands, delta-like-1 and jagged-1, is critical for glioma cell survival and proliferation. Cancer Res. 2005;65(6):2353-63.
100. Fouladi M, et al. Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Clin Oncol. 2011;29(26):3529-34.
101. Children's Oncology Group. Gamma-secretase inhibitor RO4929097 in treating young patients with relapsed or refractory solid tumors, CNS tumors, lymphoma, or T-cell leukemia [ClinicalTrials.gov identifier NCT01088763]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www. clinicaltrials.gov. Accessed 8 Nov 2012.
102. Schwartzentruber J, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012;482(7384):226-31.
103. Wu G, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet. 2012;44(3):251-3.
104. Fangusaro J. Pediatric high-grade gliomas and diffuse intrinsic pontine gliomas. J Child Neurol. 2009;24(11):1409-17.
105. Hargrave D, Bartels U, Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol. 2006;7(3):241-8.
106. Freeman CR, Farmer JP. Pediatric brain stem gliomas: a review. Int J Radiat Oncol Biol Phys. 1998;40(2):265-71.
107. Mandell LR, et al. There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a pediatric oncology group phase III trial comparing conventional vs. hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys. 1999;43(5):959-64.
108. Broniscer A, Gajjar A. Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. Oncologist. 2004;9(2):197-206.
109. Jennings MT, et al. Preradiation chemotherapy in primary high-risk brainstem tumors: phase II study CCG-9941 of the Children's Cancer Group. J Clin Oncol. 2002;20(16):3431-7.
110. Korones DN, et al. Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a Children's Oncology Group phase II study. Pediatr Blood Cancer. 2008;50(2):227-30.
111. Bouffet E, et al. Radiotherapy followed by high dose busulfan and thiotepa: a prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas. Cancer. 2000;88(3):685-92.
112. Dunkel IJ, O'Malley B, Finlay JL. Is there a role for high-dose chemotherapy with stem cell rescue for brain stem tumors of childhood? Pediatr Neurosurg. 1996;24(5):263-6.
113. Finlay JL, et al. High-dose multi-agent chemotherapy followed by bone marrow 'rescue' for malignant astrocytomas of childhood and adolescence. J Neurooncol. 1990;9(3):239-48.
114. Pediatric Brain Tumor Consortium. Capecitabine and radiation therapy in treating young patients with newly diagnosed, nonmetastatic brain stem glioma or high-grade glioma [ClinicalTrials.gov identifier NCT00357253]. US National Institutes of Health, ClinicalTrials. Gov [online]. http://www.clinicaltrials. gov. Accessed 8 Nov 2012.
115. Children's Hospital Medical Center. A study of bevacizumab therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas [ClinialTrials.gov identifier NCT00890786]. US National Institutes of Health [online]. http://clinicaltrials.gov. Accessed 8 Nov 2012.
116. St Jude Children's Research Hospital. Clinical trial evaluating the combination of vandetanib and dasatinib during and after radiation therapy (RT) in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) [ClinicalTrials.gov identifier NCT00996723]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov. Accessed 8 Nov 2012.
117. National Cancer Institute. Lenalidomide and radiation therapy in high grade gliomas or diffuse intrinsic pontine gliomas [ClinicalTrials.gov identifier NCT01222754]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov. Accessed 8 Nov 2012.
118. Gilbertson RJ, et al. ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma. Clin Cancer Res. 2003;9(10 Pt 1):3620-4.
119. Memorial Sloan-Kettering Cancer Center. External beam radiation therapy and cetuximab followed by irinotecan and cetuximab for children and young adults with newly diagnosed diffuse pontine tumors and high-grade astrocytomas [ClinicalTrials.gov identifier NCT01012609]. US National Institutes of health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov. Accessed 8 Nov 2012.
120. Zarghooni M, et al. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol. 2010;28(8):1337-44.
121. St Jude Children's Research Hospital. PDGFR inhibitor crenolanib in children/young adults with diffuse intrinsic pontine glioma or recurrent high-grade glioma [ClinicalTrials.gov identifier NCT01393912]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials. gov. Accessed 8 Nov 2012.
122. Paugh BS, et al. Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol. 2011;29(30):3999-4006.
123. Monje M, et al. Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma. Proc Natl Acad Sci USA. 2011;108(11):4453-8.
124. Roujeau T, et al. Stereotactic biopsy of diffuse pontine lesions in children. J Neurosurg. 2007;107(1 Suppl.):1-4.
125. Grill J, et al. Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma. Pediatr Blood Cancer. 2012;58(4):489-91.
126. Sievert AJ, Fisher MJ. Pediatric low-grade gliomas. J Child Neurol. 2009;24(11):1397-408.
127. Freeman CR, Farmer JP, Montes J. Low-grade astrocytomas in children: evolving management strategies. Int J Radiat Oncol Biol Phys. 1998;41(5):979-87.
128. Pollack IF. The role of surgery in pediatric gliomas. J Neurooncol. 1999;42(3):271-88.
129. Desai KI, et al. Prognostic factors for cerebellar astrocytomas in children: a study of 102 cases. Pediatr Neurosurg. 2001;35(6):311-7.
130. Fisher PG, et al. Outcome analysis of childhood low-grade astrocytomas. Pediatr Blood Cancer. 2008;51(2):245-50.
131. Pollack IF, et al. Low-grade gliomas of the cerebral hemispheres in children: an analysis of 71 cases. J Neurosurg. 1995;82(4):536-47.
132. Grabenbauer GG, et al. Radiation therapy of optico-hypothalamic gliomas (OHG): radiographic response, vision and late toxicity. Radiother Oncol. 2000;54(3):239-45.
133. Karim AB, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys. 1996;36(3):549-56.
134. Kortmann RD, et al. Current and future strategies in radiotherapy of childhood low-grade glioma of the brain. Part I: treatment modalities of radiation therapy. Strahlenther Onkol. 2003;179(8):509-20.
135. Laws ER Jr, et al. Neurosurgical management of low-grade astrocytoma of the cerebral hemispheres. J Neurosurg. 1984;61(4):665-73.
136. Shibamoto Y, et al. Supratentorial low-grade astrocytoma: correlation of computed tomography findings with effect of radiation therapy and prognostic variables. Cancer. 1993;72(1):190-5.
137. Vertosick FT Jr, Selker RG, Arena VC. Survival of patients with well-differentiated astrocytomas diagnosed in the era of computed tomography. Neurosurgery. 1991;28(4):496-501.
138. McCormack BM, et al. Treatment and survival of low-grade astrocytoma in adults: 1977-1988. Neurosurgery. 1992;31(4):636-42. (discussion 642).
139. Broniscer A, et al. Clinical and molecular characteristics of malignant transformation of low-grade glioma in children. J Clin Oncol. 2007;25(6):682-9.
140. Packer RJ, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg. 1997;86(5):747-54.
141. Lafay-Cousin L, et al. Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma: a Canadian Pediatric Brain Tumor Consortium experience. Cancer. 2008;112(4):892-9.
142. Yu DY, et al. Weekly dosing of carboplatin increases risk of allergy in children. J Pediatr Hematol Oncol. 2001;23(6):349-52.
143. Prados MD, et al. Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen. J Neurooncol. 1997;32(3):235-41.
144. Ater J, Holmes E, Zhou T, et al. Abstracts from the thirteenth international symposium on pediatric neuro-oncology: results of COG protocol A9952: a randomized phase 3 study of two chemotherapy regimens for incompletely resected low-grade glioma in young children. Neuro Oncol. 2008;10:451.
145. Massimino M, et al. High response rate to cisplatin/etoposide regimen in childhood low-grade glioma. J Clin Oncol. 2002;20(20):4209-16.
146. Lafay-Cousin L, et al. Weekly vinblastine in pediatric low-grade glioma patients with carboplatin allergic reaction. Cancer. 2005;103(12):2636-42.
147. Gururangan S, et al. Temozolomide in children with progressive low-grade glioma. Neuro Oncol. 2007;9(2):161-8.
148. Khaw SL, et al. Temozolomide in pediatric low-grade glioma. Pediatr Blood Cancer. 2007;49(6):808-11.
149. Nicholson HS, et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer. 2007;110(7):1542-50.
150. Packer RJ, et al. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer. 2009;52(7):791-5.
151. Orr LC, et al. Cytogenetics in pediatric low-grade astrocytomas. Med Pediatr Oncol. 2002;38(3):173-7.
152. White FV, et al. Nonrandom chromosomal gains in pilocytic astrocytomas of childhood. Hum Pathol. 1995;26(9):979-86.
153. Bar EE, et al. Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma. J Neuropathol Exp Neurol. 2008;67(9):878-87.
154. Jones DT, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008;68(21):8673-7.
155. Sievert AJ, et al. Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol. 2009;19(3):449-58.
156. Pediatric Brain Tumor Consortium. MEK inhibitor AZD6244 in treating young patients with recurrent or refractory low grade glioma [ClinicalTrials.gov identifier NCT01089101]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov. Accessed 8 Nov 2012.
157. New York University School of Medicine. Sorafenib in children and young adults with recurrent or progressive low-grade astrocytomas [ClinicalTrials.gov identifier NCT01338857]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov. Accessed 8 Nov 2012.
158. Dowling RJ, et al. Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta. 2010;1804(3):433-9.
159. Kwiatkowski DJ, Manning BD. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum Mol Genet. 2005;14 Spec No. 2:R251-8.
160. Napolioni V, Curatolo P. Genetics and molecular biology of tuberous sclerosis complex. Curr Genomics. 2008;9(7):475-87.
161. Inoki K, et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol. 2002;4(9):648-57.
162. Orlova KA, Crino PB. The tuberous sclerosis complex. Ann NY Acad Sci. 2010;1184:87-105.
163. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355(13):1345-56.
164. Koenig MK, Butler IJ, Northrup H. Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex. J Child Neurol. 2008;23(10):1238-9.
165. Birca A, Mercier C, Major P. Rapamycin as an alternative to surgical treatment of subependymal giant cell astrocytomas in a patient with tuberous sclerosis complex. J Neurosurg Pediatr. 2010;6(4):381-4.
166. Franz DN, et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol. 2006;59(3):490-8.
167. Lam C, et al. Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors. Pediatr Blood Cancer. 2010;54(3):476-9.
168. Krueger DA, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363(19):1801-11.
169. Gutmann DH. Using neurofibromatosis-1 to better understand and treat pediatric low-grade glioma. J Child Neurol. 2008;23(10):1186-94.
170. Listernick R, et al. Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol. 1997;41(2):143-9.
171. Dasgupta B, et al. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res. 2005;65(7):2755-60.